Skip to main content
Article thumbnail
Location of Repository

PDGF-C Induces Maturation of Blood Vessels in a Model of Glioblastoma and Attenuates the Response to Anti-VEGF Treatment

By Emmanuelle di Tomaso, Nyall London, Daniel Fuja, James Logie, James A. Tyrrell, Walid Kamoun, Lance L. Munn and Rakesh K. Jain
Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:2662415
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (in press) Edema control by cediranib, a VEGF targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.
    2. (2008). A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab alone or in combination with irinotecan (CPT-11) on 6-month progression free survival in recurrent, treatment-refractory glioblastoma. J Clin Oncol 26S: abstract 2010b.
    3. (2008). Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke.
    4. (2007). Angiogenesis in brain tumours.
    5. (2002). Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta receptors.
    6. (2007). Antiangiogenic agents for the treatment of glioblastoma.
    7. (2007). AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
    8. (2007). Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
    9. (2005). Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab’, leads to fluid accumulation and is associated with increased tumor vascularized volume.
    10. (2001). Cancer-related gene expression profiles in NF1-associated pilocytic astrocytomas.
    11. (2002). Dissecting tumour pathophysiology using intravital microscopy.
    12. (1988). Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation.
    13. (2003). Endothelial-pericyte interactions in angiogenesis.
    14. (1997). Expression in lung carcinomas of plateletderived growth factor and its receptors.
    15. (1990). Expression of platelet-derived growth factor beta-receptors on stromal tissue cells in human carcinoid tumors.
    16. (1996). Expression of platelet-derived growth factor transcripts in medulloblastomas and ependymomas.
    17. (2005). Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling.
    18. (2000). Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class.
    19. (2004). Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.
    20. (1996). Localization of platelet-derived growth factor beta receptor expression in the periepithelial stroma of human breast carcinoma.
    21. (1999). Mechanism of action and in vivo role of platelet-derived growth factor.
    22. (2008). Modes of resistance to anti-angiogenic therapy.
    23. (2005). Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial cell markers.
    24. (2006). Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis.
    25. (2009). Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts.
    26. (2001). PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo.
    27. (2000). PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor.
    28. (2008). PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis.
    29. (2009). PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment.
    30. (2001). PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor.
    31. (2001). PDGF-D, a new protease-activated growth factor.
    32. (2008). Peripheral nerve pericytes originating from the blood-nerve barrier expresses tight junctional molecules and transporters as barrier-forming cells.
    33. (1979). Platelet alpha granules contain a growth factor for fibroblasts.
    34. (2002). Plateletderived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
    35. (1987). Production of platelet-derived growth factor by cultured Wilms’ tumor cells and fetal kidney cells.
    36. (2007). Robust 3-D modeling of vasculature imagery using superellipsoids.
    37. (2003). Targeting PDGF receptors in cancer–rationales and proof of concept clinical trials.
    38. (2008). Targeting PDGF signaling in carcinoma-associated fibroblasts controls cervical cancer in mouse model.
    39. (2007). Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis.
    40. (1997). Tumor cell and connective tissue cell interactions in human colorectal adenocarcinoma. Transfer of plateletderived growth factor-AB/BB to stromal cells.
    41. (2006). Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma.
    42. (1994). Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.